Aastrom Biosciences News

Timothy Mayleben is endowed with the Esperion Therapeutics mystique . Whether that helps him rescue Ann Arbor-based biotechnology firm Aastrom Biosciences is to be determined.

Aastrom Biosciences, Inc. , a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced today that the NASDAQ Hearings Panel has granted the Company's request to remain listed on the NASDAQ Stock Market until March 31, 2010, subject to certain conditions.

Financial and Strategic Analysis Review Summary The "Aastrom Biosciences, Inc. - Financial and Strategic Analysis Review" is an in-depth business, strategic and financial analysis of Aastrom Biosciences, Inc.

Several stocks trading near $5 were moving on above-average volume during Wednesday's session.

InvestorSoup.com announces an investment report featuring Hard To Treat Diseases Inc.

Ann Arbor-based Aastrom Biosciences is launching another Phase 2 clinical trial to study the effectiveness of its cell treatment for a disease that causes chronic heart failure.

Aastrom Biosciences, Inc. , a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced that the Company will initiate its second clinical trial for the treatment of dilated cardiomyopathy , a severe disease associated with chronic heart failure, after a positive 30-day review of Aastrom's ...

Our analysts have issued complimentary analysis on the following six companies: The TJX Companies Inc.

A Kalamazoo-based startup company received investments from three groups recently that are helping it produce technology to aid in stem-cell research.

Ilhavo, Portugal a ' 28/09/2009 a ' SADIF Investment Analytics, announces a new summary due diligence report covering Keryx Biopharmaceuticals .

Aastrom Biosciences, Inc. , a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today announced that George Dunbar, President and Chief Executive Officer, will present at the Maxim Group Growth Conference.

Update On Aastrom's Cardiovascular Programs to be Presented At Transcatheter Cardiovascular Therapeutics Annual Meeting by Amit N. Patel, M.D. Momentum of Current Clinical Trial Recruitment Continues; Clinical Trial Pipeline for Severe Heart Failure Patients Expanding Aastrom Biosciences, Inc.

On this day, we have begun tracking the following companies as they have shown remarkable correction in recent days, you can access these free reports with a number of other reviews by signing up for your complimentary membership at : http://www.rothmanresearch.com/ Companies been researched today are: Patterson-UTI Energy Inc.

StockPreacher.com announces an investment report featuring biotechnology company StemCells Inc.

Adult Stem Cell Patient Treatments Progress in U.S. Phase II Cardiac and Vascular Regeneration Clinical Trials; Patient Enrollment On Track With Guidance ANN ARBOR, Mich., Sept.

Aastrom Biosciences, Inc. , a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced an executive management transition process that will strengthen and expand the senior leadership team over the next several months.

Our analysts have issued free ratings reports on the following six companies: Xilinx Inc.

Cryo-Cell International, Inc. , one of the largest and most established leaders in the stem cell sector.

Aastrom Biosciences, Inc. , a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today announced that George Dunbar, President and Chief Executive Officer, and Elmar Burchardt, MD, PhD, Vice President, Medical Affairs, will present at the BMO Capital Markets 9th Annual Focus on Healthcare ...

Aastrom Biosciences, Inc. , a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced that the Company received Issuer Alert #2009-004 from The Nasdaq Stock Market LLC .